XOMA Royalty (XOMA) Depreciation & Amortization (CF) (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Depreciation & Amortization (CF) came in at $3000.0 in Q1 2026, little changed year-on-year from $3000.0 in Q1 2025, and little changed quarter-over-quarter from $3000.0 in Q4 2025.
XOMA Royalty (XOMA) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $3000.0 for Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $3000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $11000.0 (changed 0.0% YoY), and the FY2025 annual result was $11000.0, up 10.0% from the prior year.
- Depreciation & Amortization (CF) came in at $3000.0 for Q1 2026 at XOMA Royalty, roughly flat from $3000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $4000.0 in Q3 2022 to a low of $1000.0 in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $2000.0 (2022), against an average of $2266.7.
- Across the five-year window, Depreciation & Amortization (CF) plunged 50.0% in 2022 and surged 200.0% in 2024, its largest moves.
- XOMA Royalty's Depreciation & Amortization (CF) stood at $4000.0 in 2022, then slumped by 75.0% to $1000.0 in 2023, then soared by 100.0% to $2000.0 in 2024, then surged by 50.0% to $3000.0 in 2025, then changed by 0.0% to $3000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $3000.0 (Q1 2026), $3000.0 (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 1,395.22 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 429,663.65 |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |